| Â | PEG-albumin | HES |
|---|
| Â | MAP | HR | MAP | HR |
|---|
HD | 96.6 ± 5.6 | 482.4 ± 28.8 | 100.0 ± 8.3 | 493.8 ± 20.9 |
H0 | 56.8 ± 7.2*†b | 396.8 ± 65.0*†| 43.0 ± 10.7*†| 305.3 ± 83.5*†|
H30 | 43.0 ± 7.6*†b | 342.8 ± 54.0*†| 33.3 ± 6.7*†| 376.8 ± 98.8*†|
H60 | 42.6 ± 10.3*†| 367.2 ± 34.6*†| - | - |
S30 | 46.0 ± 10.2*†| 338.2 ± 18.5*†| - | - |
S60 | 46.0 ± 11.9*†| 325.8 ± 21.0*†| - | - |
- Shown are the changes in MAP and HR between the two study groups at different time points. Baseline: MAP (mmHg) = 107.4 ± 8.2, HR (beats/minute) = 466.3 ± 24.2. Within the same treatment group: *versus baseline; †versus hemodilution. Among treatments: PEG-albumin versus bHES. HD, hemodilution; H0, beginning of hemorrhage; H30, midpoint in the hemorrhage period when most of the 60% volume has been withdrawn; H60, end of the hemorrhage period; HES, hydroxyethyl starch; HR, heart rate; MAP, mean arterial pressure; PEG-albumin, polyethylene glycol-conjugated human serum albumin; S30, 30 minutes after beginning of shock; S60, end of the experiment.
